Selected article for: "broad protection and effective protection"
Author: Jangra, Sonia; Landers, Jeffrey J.; Rathnasinghe, Raveen; O’Konek, Jessica J.; Janczak, Katarzyna W.; Cascalho, Marilia; Kennedy, Andrew A.; Tai, Andrew W.; Baker, James R.; Schotsaert, Michael; Wong, Pamela T.
Title: A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine
  • Cord-id: lttt46p4
  • Document date: 2021_9_16
    • ID: lttt46p4
    Snippet: Several SARS-CoV-2 vaccines have received EUAs, but many issues remain unresolved, including duration of conferred immunity and breadth of cross-protection. Adjuvants that enhance and shape adaptive immune responses that confer broad protection against SARS-CoV-2 variants will be pivotal for long-term protection as drift variants continue to emerge. We developed an intranasal, rationally designed adjuvant integrating a nanoemulsion (NE) that activates TLRs and NLRP3 with an RNA agonist of RIG-I
    Document: Several SARS-CoV-2 vaccines have received EUAs, but many issues remain unresolved, including duration of conferred immunity and breadth of cross-protection. Adjuvants that enhance and shape adaptive immune responses that confer broad protection against SARS-CoV-2 variants will be pivotal for long-term protection as drift variants continue to emerge. We developed an intranasal, rationally designed adjuvant integrating a nanoemulsion (NE) that activates TLRs and NLRP3 with an RNA agonist of RIG-I (IVT DI). The combination adjuvant with spike protein antigen elicited robust responses to SARS-CoV-2 in mice, with markedly enhanced T(H)1-biased cellular responses and high virus-neutralizing antibody titers towards both homologous SARS-CoV-2 and a variant harboring the N501Y mutation shared by B1.1.7, B.1.351 and P.1 variants. Furthermore, passive transfer of vaccination-induced antibodies protected naive mice against heterologous viral challenge. NE/IVT DI enables mucosal vaccination, and has the potential to improve the immune profile of a variety of SARS-CoV-2 vaccine candidates to provide effective cross-protection against future drift variants.

    Search related documents:
    Co phrase search for related documents
    • aa insertion and acute respiratory syndrome coronavirus: 1
    • absence protection provide and acute respiratory syndrome: 1
    • absence protection provide and acute respiratory syndrome coronavirus: 1
    • activity mediate and acute respiratory syndrome: 1, 2, 3, 4
    • activity mediate and acute respiratory syndrome coronavirus: 1, 2, 3, 4
    • acute cytokine response and adaptive response: 1, 2
    • acute inflammatory cytokine and adaptive response: 1
    • acute phase and adaptive response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and adaptive mutation: 1, 2, 3, 4, 5
    • acute respiratory syndrome and adaptive response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptive response improve: 1
    • acute respiratory syndrome and additional barrier: 1, 2, 3
    • acute respiratory syndrome coronavirus and adaptive mutation: 1, 2, 3, 4, 5
    • acute respiratory syndrome coronavirus and adaptive response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and adaptive response improve: 1